Detail View
Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release
WEB OF SCIENCE
SCOPUS
- Title
- Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release
- Issued Date
- 2017-06
- Citation
- Colloids and Surfaces B: Biointerfaces, v.154, pp.104 - 114
- Type
- Article
- Author Keywords
- Nanohybrid liposome ; Photothermal therapy ; Targeted drug delivery ; Hyaluronic acid ; CD44 receptor ; Breast cancer
- Keywords
- POLYMER HYBRID NANOPARTICLES ; TARGETED CO-DELIVERY ; CANCER-CELLS ; CLINICAL-APPLICATIONS ; PHOTOTHERMAL THERAPY ; SENSITIVE LIPOSOMES ; ANTITUMOR-ACTIVITY ; ANTICANCER DRUGS ; COATED LIPOSOMES ; IN-VITRO
- ISSN
- 0927-7765
- Abstract
-
The aim of this work is to prepare and evaluate a novel lipid-polymer hybrid liposomal nanoplatform (hyaluronic acid-magnetic nanoparticle-liposomes, HA-MNP-LPs) as a vehicle for targeted delivery and triggered release of an anticancer drug (docetaxel, DTX) in human breast cancer cells. We first synthesize an amphiphilic hyaluronic acid hexadecylamine polymer (HA-C-16) to enhance the targeting ability of the hybrid liposome. Next, HA-MNP-LPs are constructed to achieve an average size of 189.93 +/- 2.74 nm in diameter. In addition, citric acid-coated magnetic nanoparticles (MNPs) are prepared and embedded in the aqueous cores while DTX is encapsulated in the hydrophobic bilayers of the liposomes. Experiments with coumarin 6 loaded hybrid liposomes (C6/HA-MNP-LPs) show that the hybrid liposomes have superior cellular uptake in comparison with the conventional non-targeting liposomes (C6/MNP-LPs), and the result is further confirmed by Prussian blue staining. Under near-infrared laser irradiation (NIR, 808 nm), the HA-MNP-LPs aqueous solution can reach 46.7 degrees C in 10 min, and the hybrid liposomes released over 20% more drug than the non-irradiated liposomes. Using a combination of photothermal irradiation and chemotherapy, the DTX-loaded hybrid liposomes (DTX/HA-MNP-LPs) significantly enhance therapeutic efficacy, with the IC50 value of 0.69 +/- 0.10 mu g/mL, which is much lower than the values for DTX monotherapy. Consequently, the prepared hybrid nanoplatform may offer a promising drug delivery vehicle with selective targeting and enhanced drug release in treating CD44-overexpressing cancers. (C) 2017 Elsevier B.V. All rights reserved.
더보기
- Publisher
- Elsevier
File Downloads
- There are no files associated with this item.
공유
Total Views & Downloads
???jsp.display-item.statistics.view???: , ???jsp.display-item.statistics.download???:
